895 pharmaceutical and medication recalls tracked. Stay informed about FDA drug safety alerts, prescription medications, over-the-counter drugs, and dietary supplements.
Looking for a specific drug? Use the search page to find recalls by medication name, manufacturer, or NDC number.
Affixus recalled 22 units of its antegrade femoral nailing system on December 2, 2025, due to a risk of implant fatigue fracture. The defect may lead to serious health complications including tissue damage and pain. Consumers and healthcare providers must stop using the affected implants immediately.
Zimmer, Inc. recalled 23 units of the Affixus Antegrade Femoral Nails on December 2, 2025. The implants may have an undersized distal diameter, risking implant fatigue fracture. This defect can cause severe health issues, including pain and tissue damage requiring surgery.
Affixus recalled its Antegrade Femoral Nailing System on December 2, 2025, due to a potential implant fatigue fracture risk. The recall affects 22 units distributed nationwide in 14 states. Patients should stop using the affected devices immediately to avoid serious health risks.
Zimmer Inc. recalled 24 Affixus Antegrade Femoral Nails on December 2, 2025. Affected implants may have undersized distal diameters, leading to potential fractures. Users should stop using the product immediately and contact their healthcare provider.
Zimmer Inc. recalled 22 Affixus Antegrade Femoral Nails on December 2, 2025. The implants may have undersized distal diameters, risking implant fatigue fractures. Consumers should stop using the device immediately and follow manufacturer instructions.
Zimmer recalled 24 Affixus Antegrade Femoral Nails on December 2, 2025, due to a risk of implant fatigue fracture. Affected implants may cause serious health issues, including tissue damage and pain. Healthcare providers must stop using the device immediately and follow recall instructions.
Zimmer issued a recall for 22 Affixus Antegrade Femoral Nails on December 2, 2025. The implants may have an undersized diameter, risking fatigue fractures. This defect could lead to severe health complications for patients.
Winder Laboratories, LLC recalled 3,528 bottles of Morphine Sulfate Oral Solution on November 26, 2025. The labeling error misrepresented the product size, leading to potential dosing issues. Consumers should stop using the product immediately and consult their healthcare provider.
Cook Medical recalled 15 units of Transjugular Intrahepatic Access Sets on November 26, 2025. The devices may have been manufactured out of specification, leading to potential complications during medical procedures. Patients and healthcare providers should stop using these devices immediately.
Cook Medical recalled 7,952 Flexor Check-Flo introducers and sets on November 26, 2025. The devices may have been manufactured out of specification, potentially posing serious risks to patients. Health care providers and patients should stop using these products immediately.
Cook Medical recalled 23 units of its Transjugular Liver Access Sets on November 26, 2025. The recall follows concerns that products may have been manufactured out of specification, leading to potential use errors. Healthcare providers and patients should stop using the device immediately and follow recall instructions.
Ferndale Laboratories recalled 24,589 vials of Mastisol Liquid Adhesive due to a defect. The butyrate tube may crack during use, making the product unusable. The recall affects products distributed in the U.S. and the U.K., announced on November 25, 2025.
Alcon Laboratories, Inc. recalled 151 units of Custom Pak surgical procedure packs on November 24, 2025. The recall stems from incomplete seals that may affect sterility. Healthcare providers and patients should stop using the products immediately.
Breckenridge Pharmaceutical, Inc. recalled 7,389 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations and the presence of N-nitroso-duloxetine impurity above FDA limits. Consumers should stop using the product immediately and contact healthcare providers for guidance.
Towa Pharmaceuticals recalled 3,397 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations resulting in N-nitroso-duloxetine levels exceeding FDA limits. Consumers must stop using the product immediately.
Draeger, Inc. recalled 188 units of the Vapor 3000 anesthetic vaporizer on November 24, 2025. The devices contained impurities in a component not delivered within specification. Healthcare providers and patients must stop using the devices immediately.
Draeger, Inc. recalled 431 units of the Vapor 2000 anesthetic vaporizer on November 24, 2025. A component of the devices contained impurities and did not meet specifications, posing a high hazard risk. Healthcare providers and patients should cease use immediately and follow recall instructions.
ICU Medical recalled the LifeShield Infusion Safety Software Suite v2.2 on November 24, 2025. The software fails to operate as expected for migrated libraries, risking medication delivery errors. The recall affects seven customers across several states, including California and New York.
ICU Medical recalled LifeShield Drug Library Management software on November 24, 2025. A software issue limits concentration precision to one decimal place, risking incorrect drug dosages. Users should stop using the product immediately and follow recall instructions.
Glenmark Pharmaceuticals recalled over 11,000 bottles of Bisoprolol Fumarate and Hydrochlorothiazide Tablets on November 21, 2025. Testing revealed traces of ezetimibe, posing a health risk. Consumers should stop using the product immediately and contact their healthcare provider.
Fagron Compounding Services recalled 2,980 syringes of a topical ophthalmic solution on November 20, 2025. The recall stems from an incorrect product formulation that could pose health risks. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
A New Life Herbs recalled 49 bottles of Baby Soothe Herbal Supplement on November 20, 2025. The product misbrands due to unapproved drug claims and lack of a Supplement Facts label. Consumers should stop using the product immediately and seek a refund.
A New Life Herbs, LLC recalled 278 bottles of Boswellia Herbal Supplement on November 20, 2025. The product has unapproved drug claims and lacks a Supplement Facts label. Consumers should stop using it immediately and seek a refund.
A New Life Herbs, LLC recalled 22 bottles of Mullein flower alcohol tincture on November 20, 2025. The product is misbranded due to unapproved drug claims and lack of a Supplement Facts label. Consumers should stop using this product immediately.
Receive immediate notifications when medications you care about are recalled. Stay safe with timely FDA drug safety alerts.